+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunogenicity of semisynthetic human insulin Novo--five year prospective studies

Immunogenicity of semisynthetic human insulin Novo--five year prospective studies

Polskie Archiwum Medycyny Wewnetrznej 89(6): 492-498

The aim of the study was to compare the immunogenicity of semisynthetic human and porcine monocomponent (MC) insulin Novo during--5-year observation. Thirty-one diabetic patients, never previously treated with insulin were randomly allocated to treatment with one of the two coded insulin preparations in a double blind trial. 15 patients aged 20-58 years (mean age--36 years) were treated with human insulin and 16 diabetics aged 19-61 years (mean age--34 years) with MC pork insulin. The insulin was injected twice a day (Actrapid plus Monotard). Serum insulin-binding antibodies were determined according to Christiansen (radioimmunoelectrophoretic method). The development of insulin-binding antibodies during the first year of observation was more rapid in patients treated with MC pork insulin but thereafter it was similar in the two studied groups. After 5 years of treatment with human insulin serum insulin-binding antibodies were found in 14 patients. The level of antibodies was very low (< 0.130 mU/ml) in 5 subjects, low (0.171-0.401 mU/ml) in 6 patients and relatively high (0.885; 1.186; 5, 162 mU/ml) in 3 patients. In the group of diabetics treated with MC pork insulin after 5 years of observation serum insulin-binding antibodies were found in 12 patients. The level of antibodies was low (0.131-0.576 mU/ml) in 9 subjects and relatively high (1.034; 3.954; 5.639 mU/ml) in 3 patients. The results obtained after 2-5 years of the study did not differ significantly (Wilcoxon's test, p > 0.05).

(PDF emailed within 1 workday: $29.90)

Accession: 046333027

Download citation: RISBibTeXText

PMID: 8415211

Related references

Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porcine monocomponent insulin. Acta Diabetologica Latina 23(2): 101-106, 1986

Immunogenicity of semisynthetic human insulin. Acta Medica Polona 27(1-2): 45-50, 1986

Immunogenicity of bovine, porcine and semisynthetic human insulin. Netherlands Journal of Medicine 28 Suppl 1: 57-58, 1985

Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care 6 Suppl 1: 43-48, 1983

Comparison of porcine insulin and human insulin (Novo) using the glucose-controlled insulin infusion system, glucose-insulin dose-response curves, and the outpatient effectiveness of human insulin (Novo) in insulin-dependent diabetes. Diabetes Care 6 Suppl 1: 29-34, 1983

Treatment of type 1 diabetes with semisynthetic human insulin. 1 year's experience. Minerva Endocrinologica 9(2): 125-135, 1984

Diurnal rhythm of meal related insulin requirements in intensified insulin therapy using long acting semisynthetic human zinc insulin as basal insulin dose. Diabetes Research & Clinical Practice (SUPPL 1): S531, 1985

Clinical and immunologic studies of semisynthetic human monocomponent insulin u 100 in diabetic children. Journal of the Japan Diabetes Society 30(3): 225-231, 1987

Immunogenicity of MC Lente Novo insulin. Polskie Archiwum Medycyny Wewnetrznej 76(3): 172-176, 1986

Comparison of semisynthetic human insulin and porcine insulin in diabetic patients with or without circulating anti-insulin antibodies. Acta Clinica Belgica 38(6): 360-368, 1983

Miscibility of semisynthetic human ultralente insulin with short-acting insulin in insulin-dependent diabetic patients. Acta Diabetologica Latina 25(3): 263-269, 1988

A comparison of semisynthetic human NPH insulin and porcine NPH insulin in the treatment of insulin-dependent diabetes mellitus. Diabetic Medicine 4(4): 304-306, 1987

Insulin antibodies in non-insulin-dependent diabetes mellitus: effect of treatment with semisynthetic human insulin. Clinical Therapeutics 11(2): 268-277, 1989

Effectiveness of treatment of insulin-dependent diabetes with single dose of mixture of three kinds of insulin, employing semisynthetic human insulin. Diabete & Metabolisme 15(3): 147-148, 1989

Human (semisynthetic) insulin and porcine insulin in the treatment of non-insulin-dependent diabetes. A double-blind, comparative clinical trial. Medical Journal of Australia 140(4): 200-202, 1984